MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.…
MoonLake Immunotherapeutics (MLTX) Stock Could Be Above Fair Value On Book Value Concerns
MoonLake Immunotherapeutics (NASDAQ: MLTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 130 employees.
The shares were at 11.07 USD on 20 November 2026, up 4.1% over 52 weeks. Its 52-week range is 9.460 USD to 23.29 USD: the price is 52.5% below the high and 17.0% above the low.
Its market capitalisation is 942.13M USD.
MoonLake Immunotherapeutics reports return on equity of -74.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 396.85M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 30.29 USD is 173.6% above the current price. The next earnings report is expected on 24 February 2027.